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ABSTRACT 
A retrospective study was undertaken to assess cancers in northern Thailand using the Chiang Mai Cancer registry 
and Maharaj Nakorn Chiang Mai Hospital records from January 2001 to December 2005. Maharaj Nakorn Chiang Mai 
Hospital is the university hospital for the Faculty of Medicine, Chiang Mai University. There were 4,108 new cancer 
cases being treated at the institution. The distribution of patients were (a) 32% from Chiang Mai, (b) 42% from nearby 
provinces of Lampoon, Phayao, and Chiang Rai, (c) 20.4% from other northern provinces, and (d) 1.2% from other parts 
of Thailand. Based on the data, the most common cancers by relative frequency are cancers of the lung, cervix, liver, 
breast, and non-Hodgkin's lymphoma. The current treatment options used to manage these most common cancers are 
described in this article. © 2008 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Cancer is one of the major public health problems in 
Thailand. In 2002, cancer became the third common 
cause of death in the Northern part of Thailand [1]. A 
retrospective analysis was undertaken to assess the 
cancers in Northern Thailand. The sources for this data 
analysis were the Chiang Mai Cancer Registry and 
Maharaj Nakorn Chiang Mai Hospital, using the medical 
records of patients from January 2001 to December 2005. 
Maharaj Nakorn Chiang Mai Hospital is the university 
hospital of the Faculty of Medicine, Chiang Mai 
University. The hospital has 1,800 beds and serves about 
415,000 out-patients and 49,200 in-patients each year.  
MATERIALS AND METHODS 
In 2005, there were 4,108 cases of new invasive 
cancer at Maharaj Nakorn Chiang Mai Hospital [2]. 
Thirty-six percent were Chiang Mai residents, 42.0% 
came from nearby provinces (Lampoon, Lampang, 
Phayao and Chiang Rai), 20.4% came from the other 
provinces in the northern region, and only 1.2% resided 
outside the northern part of Thailand (Table 1).  
 
 * Corresponding author. Present address:  
Division of Therapeutic Radiology and Oncology, Faculty of Medicine, 
Chiang Mai University, Thailand.  
E-mail: pimkhuan@mail.med.cmu.ac.th  
(Pimkhuan Kamnerdsupaphon). 
Available online at http://www.biij.org/2008/3/e46
doi: 10.2349/biij.4.3.e46 
Age and sex 
There were 1,810 male and 2,298 female cancer 
cases in the year 2005, with a male-to-female ratio of 
1:1.3, but 1,135 (49.4%) of the cancers in females 
occurred in sex-specific sites (i.e. breast and reproductive 
organs) while only 80 cases (4.4%) of sex-specific 
cancers (i.e. prostate, testis, and penis cancers) occurred 
in males. When sex-specific sites were excluded, the 
male-to-female ratio increased to 1.5:1 [2]. 
Ages ranged from below one year to 98 years. The 
median age at diagnosis was 55 years, 57.3 years for 
males and 59 years for females. In the age group of 25 to 
59, there were more female cancer patients than males, 
while in the age group above 60, there were more male 
cancer patients than female cancer patients (Fig. 1). 
There were 100 cases of cancer in children (below age 
15), accounting for only 2.4% of all cases, but there were 
1,618 cases in the old-age group (age 60 and above), 
accounting for 39.4% of all cases [2]. 
There were 214 in situ patients and they were not 
included in this analysis. Uterine cervical cancer in situ 
was the most common, accounting for 63.6% of cases.  
Stage of disease 
Twenty eight percent were diagnosed at an 
advanced stage (20.3% distant metastasis and 8.3% 
regional node metastasis), and 55.9% were diagnosed at 
a localised stage and locally advanced. In 835 cases of 
distant metastasis, 13.2% had multiple sites of metastasis. 
The most common site of distant metastasis was lung 
(21.7%), followed by distant lymph nodes (21.4%), liver 
(16.5%), bone (14.0%), and brain (12.6%). 
Leading sites of cancer cases 
Of the invasive cancer in both sexes combined, lung 
cancer was the most common (14.1%), followed by 
cervix, liver, breast, and non-Hodgkin’s lymphoma 
(Table 2). Together these five types of cancer accounted 
for 51.2% of all new cancers. For males, the most 
common cancer was lung cancer, accounting for 19.8% 
of all new cases, followed by liver cancer, non-
Hodgkin’s lymphoma, nasopharyngeal cancer and rectal 
cancer. For females, the most common cancers were 
cervix cancer, accounting for 23.7% of all new cases, 
followed by breast, lung, ovary, and liver cancer. 
Childhood cancer 
Approximately 24 percent of Thailand's population 
is younger than 15 years old [3]. At Maharaj Nakorn 
Chiang Mai Hospital, there were 100 cases of childhood 
cancers (ages below 1 to 14), accounting for 2.4% of all 
cancer cases in 2005. The most common childhood 
cancer was leukaemia, accounting for 49.0% of 
childhood cancers, followed by brain and nervous system 
(13.0%), NHL (6.0%), bone (5.0%), and eye (5.0%). 
Leukaemia, brain and nervous system were the common 
causes of death in childhood cancers. 
Primary Treatment 
In 2004, there were 18.8% of cancer patients who 
received symptomatic treatment alone due to advanced 
disease or patient refusal. The other 81.2% received 
definitive treatment [1]. The majority of the patients 
received single modality treatment and the most common 
primary treatment was surgery, followed by 
chemotherapy, and radiation therapy (Table 3). 
Table 1  Locations of the invasive cancer cases. 
Location cases  % 
NORTHERN REGION  4042  98.4 
Chiang Mai  1479  36.0 
Chiang Rai  648  15.8 
Lampoon 503  12.2 
Phayao 375  9.1 
Lampang 198  4.8 
Nan 197  4.8 
Phrae 175  4.3 
Mae Hong Son  160  3.9 
Tak 108  2.6 
Sukhothai 77  1.9 
Uttaradit 57  1.4 
Kamphaingphet 19  0.5 
Phitsanuloak 16  0.4 
Phichit 11  0.3 
Phetchabun   10  0.2 
Nakhon Sawan  6  0.1 
Uthai Thani  3  0.1 
CENTRAL REGION  36  0.9 
NORTH-EASTERN REGION  8  0.2 
SOUTHERN REGION  4  0.1 
FOREIGNERS 19  0.5 
TOTAL 4108  100.0 
0
50
100
150
200
250
300
350
400
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
Age
C
a
s
e
s
MALE FEMALE
 
Figure 1  Age distribution of new cancer cases in Maharaj 
Nakorn Chiang Mai Hospital, 2005. 
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Table 2  The 10 leading malignancies in Maharaj Nakorn Chiang Mai Hospital, 2005. 
  Males  cases  %   Females  cases  %   Both  sexes  cases  % 
1 Lung  359  19.8  Cervix    544 23.7  Lung  578  14.1 
2 Liver  319  17.6  Breast  324 14.1  Cervix  544  13.2 
3 NHL  114  6.3  Lung  219 9.5  Liver  433  10.5 
4 Nasopharynx  77  4.0  Ovary    143 6.2  Breast  333  8.1 
5 Bladder  72  4.0  Liver  115 5.0  NHL  217  5.3 
6 Rectum  61  3.4  NHL  103 4.5  Ovary    143  3.5 
7 Colon  60  3.3  Corpus  94 4.1  Colon  119  2.9 
8 Stomach  57  3.1  Thyroid  74 3.2  Rectum  115  2.8 
9 Leukaemia  52  2.9  Colon    59 2.6  Nasopharynx  107  2.6 
10 Prostate  48  2.7  Rectum  54 2.3  Thyroid  100  2.4 
 
 
 
 
Table 3  Type of Primary Treatment for Cancers in 2004. 
Type of Treatment  Cases  % 
Single Modality  2,176  77.6 
 Surgery  1,208  43.1 
 Chemotherapy  553  19.7 
 Radiotherapy  414  14.8 
 Others  1  0.0 
Combined modalities  628  22.4 
  Surgery + Chemotherapy  332  11.8 
  Surgery + Radiotherapy  137  4.9 
 Radiotherapy  +  Chemotherapy  107  3.8 
  Surgery + Radiotherapy + Chemotherapy  47  1.7 
 Others  5  0.2 
Total 2,804  100.0 
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Figure 2  Number of new cases of lung cancer by sex, 1996-
2005. 
Figure 3  Incidence rates of new cases of lung cancer by 
sex, 1996-2005. 
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DISCUSSION 
This retrospective study shows that lung cancer and 
cancer of the cervix are the two most common cancers in 
Northern Thailand. A comprehensive report on the 
characteristics, diagnosis and staging, and treatment is 
presented in the management of these diseases. 
Lung cancer 
Lung cancer is defined as one of the major health 
problems in Thailand and has been the most common 
cause of death since 1999 [4]. Lung cancer in Thailand is 
the second most common cancer in males after liver 
cancer and the fourth in females after cervix, breast and 
liver cancers. There is a higher incidence rate of lung 
cancer in northern Thailand than other areas [5]. In 2005, 
there were 535 new cases of lung cancer diagnosed in 
2005 (326 males, 209 females) (Figure 2 and 3) in 
Northern Thailand. This constituted 25.6% of all cancers 
in males and 14.9% of those in females. The age-
standardised incidence rates were 38.0 for males and 
21.7 for females. Lung cancer has ranked first for new 
male cancers in Chiang Mai since the first population-
based registration in 1983 until 2005 in this report. For 
females, lung cancer ranked third in 2005 after breast 
and cervix cancers. The incidence rates increased with 
age in both sexes, with the rates in males increasing 
sharply after the age of 45 years and exceeding those in 
females. The cumulative rate percent to age 75 were 
4.9% for males and 2.7% for females. The risk of men 
developing lung cancer by the age of 75 years was 10 in 
205 for men and 10 in 376 for women. 
Among the 534 deaths from lung cancer, 327 were 
males (28.9% of all male cancer deaths) and 207 were 
females (24.0% of all female cancer deaths). The age-
standardised mortality rates were 38.5 for males and 21.9 
for females, and these rates were increased in both sexes 
(Figure 4). The mortality rates increased with age in both 
sexes, with rates in males increasing sharply after the age 
of 45 years and exceeding those in females (Figure 5). 
Among lung cancer deaths, 375 cases (70.2%) died 
within one year of diagnosis and 116 cases (21.7%) died 
in the second year. 
Diagnosis and stage of lung cancer  
Fifty percent of cases were diagnosed in advanced 
stage (36.6% had distant metastasis, 13.1% had regional 
nodes metastasis). The most common metastasis site was 
distant lymph nodes, followed by brain (Table 4). One 
hundred and thirty cases (40.7%) were diagnosed by 
clinical diagnosis and 85 cases were diagnosed by death 
certificate only. The common cell types were 
adenocarcinoma (30.1%) and squamous cell carcinoma 
(15.7%). 
In terms of diagnosis and staging for lung cancer, 
plain film chest radiography and computed tomography 
(CT) of the chest and upper abdomen including the liver 
and adrenal glands are necessary. For endobronchial 
lesions, pathologic diagnosis can be obtained from 
bronchoscopic biopsy or CT-guided needle biopsy. 
Mediastinoscopy and biopsy of mediastinal nodes are 
commonly performed during preoperative assessment of 
patients with resectable lung cancer. Pulmonary function 
tests are utilised to identify patients at high risk of 
surgical complications. At present, the routine screening 
for lung cancer in heavy smokers using CT scans is not 
implemented. 
Treatment of Lung Cancer 
Various platinum-based chemotherapy regimens 
have been utilised in combination with radiotherapy. 
Cisplatin-based chemotherapy regimens such as cisplatin 
plus etoposide are commonly used. Other regimens 
including carboplatin/cisplatin plus paclitaxel, 
Cisplatin/carboplatin plus gemcitabine and Cisplatin plus 
vinorelbine have also been utilised. 
Palliative thoracic radiotherapy is commonly used 
for relieving symptoms caused by advanced disease. 
Various total dose and fraction arrangements were 
considered for controlling symptoms: 13 Gy given in 
2  fractions, or 8 Gy single-fraction, or 20 Gy over 
5 fractions are commonly used. Whole brain radiation is 
usually indicated for stage IV non-small cell lung cancer 
with intracranial metastases. Prophylactic cranial 
irradiation is recommended for small cell lung cancer 
patients with good response from the primary treatment. 
Palliative radiotherapy for bone pain and prevention of 
fractures in weight-bearing bones among patients with 
bone metastasis is commonly used. 
Cervix cancer 
There were 234 new cases of cervix cancer 
diagnosed in 2005. This was 10.3% of all cancers in 
females. The age-standardised incidence rates were 22.7 
and tend to be slightly decreased (Fig 7). Cervix cancer 
was one of the three most common cancers in females. In 
2005, cervix cancer ranked second after breast cancer. 
The incidence rates increased sharply after the age of 25 
and were more common than breast and lung cancers in 
the age group 15-44 years. The mean age at diagnosis 
was 50.4 years and the median age at diagnosis was 48 
years. The cumulative rate percent to age 75 were 2.3%, 
representing a 1 in 44 risk for women developing cervix 
cancer by the age of 75 years. 
Screening for cervical cancer uses the Pap test to 
detect the presence of premalignant or malignant cells of 
the uterine cervix. Although human papilloma virus 
(HPV) is a major risk factor for uterine cervical cancer, 
testing for HPV deoxyribonucleic acid (DNA) is not a 
component in the routine screening of cervical cancer in 
Northern Thailand. 
There were 89 deaths from cervix cancer, 
accounting for 10.3% of all female cancer deaths. The 
age-standardised mortality rates were 9.3 and tend to be 
decreased after 1998 (Fig. 8). The mortality rates 
increased with age, and increased sharply after the age of 
55 years (Fig 9). 
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Figure 4  Mortality rate of lung cancer by sex, Chiang 
Mai, 1996-2005. 
Figure 5  Age-specific mortality rate of lung cancer, Chiang 
Mai, 2005. 
 
 
 
 
Table 4  Histological Cell type and Staging of Lung Cancer  
 males females  both  %   cases  %
Adenocarcinoma 96  65  161 30.1   Localised  23  4.3
Squamous cell  55  29  84 15.7   Locally advanced  148  27.7
Small cell  21  7  28 5.2   Regional node metastasis  70  13.1
Large cell  8  15  23 4.3   Distant metastasis  196  36.6
Others 16  5  21 3.9   Unknown/not  stage  98  18.3
Clinical diagnosis  130  88  218 40.7      
All 326  209  535   All    535 
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Figure 6  Number of new cases of cervix cancer by sex, 
1996-2005. 
Figure 7  Incidence rates of new cases of cervix cancer by 
sex, 1996-2005. 
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Figure 8  Mortality rate of cervix cancer by sex, Chiang 
Mai, 1996-2005. 
Figure 9 Age-specific  mortality  rate of cervix cancer, 
Chiang Mai, 2005. 
 
 
 
 
 
 
 
 
 
 
 
Table 5  Histological Cell type and Staging of Lung Cancer  
Cell type  males  females  both %   Stage  cases  %
Squamous cell ca.  -  185  185 79.1   Localised  112  47.9
Adenocarcinoma -  40  40 17.1   Locally  advanced  104  44.4
Others -  6  6 2.6   Regional  node  metastasis  6  2.6
Clinical diagnosis  -  3  3 1.3   Distant metastasis  6  2.6
       Unknown/not  stage  6  2.6
All   234  234 100.0   All    234  100.0
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Among cervix cancer deaths, 24 cases (27.0%) 
survived more than five years, 34 cases (38.2%) survived 
more than three years and 15 cases (16.9%) survived less 
than one year. 
Diagnosis and stage of cancer  
There were 223 cases of carcinoma in situ of cervix 
uteri which were not included in this analysis. The most 
widely accepted staging system for cervical cancer is the 
FIGO (International Federation of Gynecology and 
Obstetrics) system. Among the invasive cancers, 
112 cases (47.9%) were diagnosed in localised stage and 
6 cases had distant metastasis. The most common 
metastasis site was intra-peritoneum seedling. Ninety-
eight percent were histologically diagnosed and the 
common cell types were squamous cell carcinoma 
(79.1%) and adenocarcinoma (17.1%) (table 5). 
The patient is staged by physical examination 
including a bimanual pelvic examination with attention 
to parametria and pelvic side walls, rectovaginal 
examination, as well as examination of regional lymph 
nodes. Imaging studies recommended include chest 
radiography, intravenous pyelography (IVP) and 
computed tomography (CT). In some situations magnetic 
resonance imaging (MRI) will help to identify local 
involvement of the disease, as well as evidence of 
metastatic spreading. Cystoscopy or proctoscopy is 
indicated in advanced diseases in which bladder and /or 
rectal involvement are suspected.  
Treatment of Cervical Cancer 
Surgery 
Surgery alone can be utilised for carcinoma in situ 
(CIS), stage IA1-2 and IB1. Primary surgery is often 
chosen for younger patients to preserve ovarian function. 
Surgery is commonly used in conjunction with 
chemotherapy and radiation therapy for patients with 
bulky disease. 
Radiation Therapy 
Radiotherapy alone can also be used for CIS, stage 
IA1-2 , and IB1 disease but is often chosen for older 
patients to avoid surgical risks. Radiation can be 
delivered with external beam and/or intracavitary 
approaches. Postoperative radiotherapy is recommended 
in patients whose disease exhibits high-risk features 
including bulky tumours, lymphovascular invasion, deep 
cervical stromal invasion, positive lymph nodes, and 
positive margins. Radiation therapy is delivered with 
concurrent chemotherapy for patients with stage IB, II, 
III and IVA cancers. 
Chemotherapy 
Current chemotherapy recommendations are 
platinum-based regimens. Cisplatin-based chemotherapy 
concurrent with radiotherapy affords improved 
locoregional control and survival and is the standard of 
care in Northern Thailand. 
This study referred to only the northern part of 
Thailand, However, the data and findings are important 
for the planning and delivery of the most appropriate and 
effective health services for the regional population. The 
authors recommended that cancer registry is one of the 
best methods for handling cancer problems in Thailand 
in terms of serving and guiding the health care plan. 
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